PLoS One:发现调节前列腺癌发展的miRNA以及治疗药物

2012-04-10 Deepblue 生物谷

去势抵抗性前列腺癌 (CRPC) 的发生促进了前列腺癌(PCa)病人的高死亡率,这在某种程度上归因于肿瘤干细胞(CSCs)的存在及出现。近期来自美国韦恩州立大学医学院的Fazlul H. Sarkar等人研究表明,解除对Let-7(一种miRNAs)表达的控制会促进PCa的发生和发展,并且这个过程能够被BR-DIM所改变。相关研究发表在3月19日美国《公共科学图书馆·综合(PLoS One)上。

去势抵抗性前列腺癌 (CRPC) 的发生促进了前列腺癌(PCa)病人的高死亡率,这在某种程度上归因于肿瘤干细胞(CSCs)的存在及出现。近期来自美国韦恩州立大学医学院的Fazlul H. Sarkar等人研究表明,解除对Let-7(一种miRNAs)表达的控制会促进PCa的发生和发展,并且这个过程能够被BR-DIM所改变。相关研究发表在3月19日美国《公共科学图书馆·综合(PLoS One)上。

在几种已知的miRNAs中,let-7家族通过调节CSCs在引起PCa的复发以及发展中起到了重要作用。然而,let-7家族促进PCa侵略性的机制还未可知。Zeste homolog 2(EZH2)的增强子是一个公认的let-7家族的目标,在过去被证明其可以控制干细胞功能。在这项研究中,研究人员发现,在人类 PCa组织样品中,尤其是在更高Gleason等级的肿瘤中,失去let-7 家族与EZH2的过表达一致。在PCa 细胞中,通过转染 let-7前体细胞,let-7的过表达会减少EZH2的表达,并抑制克隆及球体形成的能力,这与抑制EZH2 3′UTR荧光素酶的活性后效果一致。研究人员还发现,对PCa细胞使用用BR-DIM (3,3′-二吲哚甲烷)治疗后,会上调let-7并下调EZH2的表达,这与抑制自我更新和克隆能力一致。

此外,在我们正在做的二期临床实验中,BR-DIM的介入治疗先于根治性前列腺切除术。结果表明:使用BR-DIM治疗后, PCa组织样本中let-7 的上调与EZH2的表达下调一致。这些结果表明,失去 let-7会调停EZH2的增强型表达,然后促进PCa的侵略性,而这些都可以通过BR-DIM的治疗来改变。因此,BR-DIM可能有一定的临床药物。(生物谷Deepblue编译)

doi: 10.1371/journal.pone.0033729
PMC:
PMID:

Loss of Let-7 Up-Regulates EZH2 in Prostate Cancer Consistent with the Acquisition of Cancer Stem Cell Signatures That Are Attenuated by BR-DIM

Dejuan Kong, Elisabeth Heath, Wei Chen, Michael L. Cher, Isaac Powell, Lance Heilbrun, Yiwei Li, Shadan Ali, Seema Sethi, Oudai Hassan, Clara Hwang, Nilesh Gupta, Dhananjay Chitale, Wael A. Sakr, Mani Menon, Fazlul H. Sarkar.

The emergence of castrate-resistant prostate cancer (CRPC) contributes to the high mortality of patients diagnosed with prostate cancer (PCa), which in part could be attributed to the existence and the emergence of cancer stem cells (CSCs). Recent studies have shown that deregulated expression of microRNAs (miRNAs) contributes to the initiation and progression of PCa. Among several known miRNAs, let-7 family appears to play a key role in the recurrence and progression of PCa by regulating CSCs; however, the mechanism by which let-7 family contributes to PCa aggressiveness is unclear. Enhancer of Zeste homolog 2 (EZH2), a putative target of let-7 family, was demonstrated to control stem cell function. In this study, we found loss of let-7 family with corresponding over-expression of EZH2 in human PCa tissue specimens, especially in higher Gleason grade tumors. Overexpression of let-7 by transfection of let-7 precursors decreased EZH2 expression and repressed clonogenic ability and sphere-forming capacity of PCa cells, which was consistent with inhibition of EZH2 3′UTR luciferase activity. We also found that the treatment of PCa cells with BR-DIM (formulated DIM: 3,3′-diindolylmethane by Bio Response, Boulder, CO, abbreviated as BR-DIM) up-regulated let-7 and down-regulated EZH2 expression, consistent with inhibition of self-renewal and clonogenic capacity.Moreover, BR-DIM intervention in our on-going phase II clinical trial in patients prior to radical prostatectomy showed upregulation of let-7 consistent with down-regulation of EZH2 expression in PCa tissue specimens after BR-DIM intervention. These results suggest that the loss of let-7 mediated increased expression of EZH2 contributes to PCa aggressiveness, which could be attenuated by BR-DIM treatment, and thus BR-DIM is likely to have clinical impact..

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1930345, encodeId=f497193034589, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Nov 19 13:45:00 CST 2012, time=2012-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789395, encodeId=7f771e8939559, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Oct 06 06:45:00 CST 2012, time=2012-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921592, encodeId=0e0e19215920a, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Mon Sep 17 06:45:00 CST 2012, time=2012-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312239, encodeId=8c9c13122390b, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Thu Apr 12 14:45:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
    2012-11-19 smallant2002
  2. [GetPortalCommentsPageByObjectIdResponse(id=1930345, encodeId=f497193034589, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Nov 19 13:45:00 CST 2012, time=2012-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789395, encodeId=7f771e8939559, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Oct 06 06:45:00 CST 2012, time=2012-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921592, encodeId=0e0e19215920a, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Mon Sep 17 06:45:00 CST 2012, time=2012-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312239, encodeId=8c9c13122390b, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Thu Apr 12 14:45:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1930345, encodeId=f497193034589, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Nov 19 13:45:00 CST 2012, time=2012-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789395, encodeId=7f771e8939559, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Oct 06 06:45:00 CST 2012, time=2012-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921592, encodeId=0e0e19215920a, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Mon Sep 17 06:45:00 CST 2012, time=2012-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312239, encodeId=8c9c13122390b, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Thu Apr 12 14:45:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1930345, encodeId=f497193034589, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Nov 19 13:45:00 CST 2012, time=2012-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789395, encodeId=7f771e8939559, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Oct 06 06:45:00 CST 2012, time=2012-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921592, encodeId=0e0e19215920a, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Mon Sep 17 06:45:00 CST 2012, time=2012-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312239, encodeId=8c9c13122390b, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Thu Apr 12 14:45:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
    2012-04-12 Homburg

相关资讯

PNAS:尤涵等解析神经母细胞瘤分化机制

近日,国际权威学术期刊美国《国家科学院院刊》(PNAS)上发表了厦门大学生命科学学院的研究人员的研究论文,揭示了FOXO调控神经母细胞瘤分化的分子机制。 神经母细胞瘤(NB)是儿童常见的恶性肿瘤,年发病率大约为1/10万,仅低于白血病和中枢神经肿瘤。在神经母细胞瘤的发病过程中一个关键的早期事件就是成神经细胞不同阶段的分化停滞。利用TPA和PDGF-BB促使成神经瘤细胞终末分化可作为有效治疗神经细

Cell Reports:科学家破解癌细胞耐受药物MLN4924秘密

基于PDB文件1ndd利用PyMOL渲染构建NEDD8蛋白结构图,图片来自维基共享资源。 【Copyright ©版权Bioon.com所有,若未得到生物谷授权,请勿转载。】 对癌症患者而言,耐药性是一个严重性问题:药物治疗刚开始有一些疗效,但是过一段时间之后,不能发挥作用。如今,来自美国桑福德-伯纳姆医学研究所(Sanford-Burnham Medical Research In

J. Exp. Med.:阻断CDK蛋白可导致三阴性乳腺癌萎缩

根据PDB文件1nkp而构建出c-Myc(红色)与Max(蓝色)和DNA形成的复合物的结构。图片来自维基共享资源。 根据2012年3月9日发表在Journal of Experimental Medicine期刊上的一篇研究论文,抑制一种大量存在的促进生长的蛋白能够导致三阴性乳腺癌消退。 三阴性乳腺癌(triple-negative breast tumor)缺乏其他类型乳腺癌中存在的所有已知

Nat Biotechnol:治疗皮肤癌的黑色素瘤疫苗研究获新突破

梅奥诊所研究人员将人黑色素瘤细胞的DNA与一种狂犬病病毒进行基因组合后,提高老鼠的免疫系统功能进而根除皮肤癌。这种战略称为癌症的免疫疗法,即采用基因工程改造过的水泡性口炎病毒直接将黑色素瘤细胞来源的广谱基因传递带肿瘤内。在早期的研究中,60%的荷瘤小鼠在不到3个月的时间内就得到治愈,并且副作用也很少。 最新研究结果发表在本周的《自然生物技术》杂志上。 梅奥诊所分子医学系研究人员、文章合著者

JBC:肿瘤生物标记物hMSH2的识别机制

核蛋白hMSH2是DNA错配修复系统中的重要元件。之前的研究表明,hMSH2很可能是TCRγδ的一种蛋白配体。近日,来自中国医学科学院基础医学研究所的何维教授及其研究组发现:异位表达的人类肿瘤生物标记物hMSH2是一个新发现的内源性配体,可以被人类Vδ2 T细胞识别并引起先天的抗肿瘤抗病毒免疫反应。相关论文发表在3月20日的美国《生化周刊》(Journal of Biological Chemis

EMBO Mol Med:鉴定癌症类型的新技术

犹他州大学Huntsman癌症研究所的研究人员称他们已经发现了一种快速、准确且成本低廉的方法来确定引发癌症的遗传物质的重组即染色体易位情况。有关该方法的描述和研究结果发表在EMBO Molecular Medicine杂志上。 许多癌症类型是由肿瘤细胞中染色体易位导致的。虽然已发现数百种引发癌症的染色体易位,但目前检测方法有重大缺陷。 犹他州大学Huntsman癌症研究所主任Stephen